<DOC>
	<DOCNO>NCT00770224</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody , iodine I 131 tositumomab , find cancer cell carry cancer-killing substance without harm normal cell . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Giving radiolabeled monoclonal antibody together rituximab combination chemotherapy may kill cancer cell . PURPOSE : This phase II trial study side effect give iodine I 131 tositumomab together rituximab combination chemotherapy see well work treat patient previously untreated stage II , stage III , stage IV follicular non-Hodgkin lymphoma .</brief_summary>
	<brief_title>S0801 Iodine I 131 Tositumomab , Rituximab , Combination Chemotherapy Previously Untreated Stage II , Stage III , Stage IV Follicular Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate response rate patient previously untreated stage II-IV follicular non-Hodgkin lymphoma treat rituximab , cyclophosphamide , doxorubicin hydrochloride , vincristine sulfate , prednisone ( R-CHOP ) combination iodine I 131 tositumomab . - To evaluate toxicity regimen patient . - To estimate 3-year progression-free survival rate patient treat regimen . - To estimate 5-year progression-free overall survival rate patient treat regimen . - To assess safety profile regimen patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive R-CHOP* comprise rituximab IV , cyclophosphamide IV , doxorubicin hydrochloride IV , vincristine sulfate IV day 1 oral prednisone daily day 1-5 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients least stable disease proceed consolidation therapy . NOTE : *Patients receive R-CHOP course 1-4 CHOP alone course 5 6 . - Consolidation therapy : Within 12 week completion induction therapy , patient receive tositumomab IV 1 hour follow dosimetric dose iodine I 131 tositumomab IV 20 minute . Patients undergo whole body gamma camera scan 1-week period determine rate total body clearance radioactivity therapeutic dose iodine I 131 tositumomab . Within 7-14 day dosimetric dose , patient receive tositumomab IV 1 hour follow therapeutic dose iodine I 131 tositumomab IV 20 minute . Patients least stable disease proceed maintenance therapy . - Maintenance therapy : Beginning approximately 1 year study entry 28 day restaging , patient receive rituximab IV every 3 month 4 year ( 16 course ) absence disease progression unacceptable toxicity . After completion maintenance therapy , patient follow annually 7 year . Patients complete maintenance therapy follow every 6 month 2 year annually 7 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* grade 1 , 2 , 3 follicular Bcell nonHodgkin lymphoma meeting follow criterion : Bulky stage II stage III IV disease Diffuse large cell component must &lt; 25 % biopsy Confirmed cluster differentiation antigen 20 ( CD20 ) antigenpositive disease NOTE : *Needle aspiration cytology consider adequate pathology review Patient must unilateral bilateral bone marrow aspirate biopsy perform within 42 day Positive biopsy perform &gt; 42 day &lt; 6 month allow Previously untreated disease Bidimensionally measurable disease No clinical evidence central nervous system ( CNS ) involvement lymphoma PATIENT CHARACTERISTICS : Zubrod performance status 02 Cardiac ejection fraction â‰¥ 45 % multigated acquisition scan ( MUGA ) ECHO No significant cardiac abnormalities No known HIV positivity No requirement continuous supplemental oxygen therapy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer patient currently complete remission Not pregnant nursing Fertile patient must use effective contraception 12 month completion maintenance therapy PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , antibody therapy lymphoma No prior solid organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
</DOC>